Company Overview of PaxVax, Inc.
PaxVax, Inc., a biotechnology company, engages in developing, commercializing, and distributing candidate oral preventative vaccines against various infectious diseases. Its products include an oral vaccine technology platform based on adenovirus, which is a common virus. The company’s platform includes various disposable manufacturing processes and formulations in room temperature stability. It offers its products for influenza, cholera, anthrax, malaria, and HPV infectious diseases. The company was incorporated in 2006 and is based in San Diego, California.
3985A Sorrento Valley Boulevard
San Diego, CA 92121
Founded in 2006
Key Executives for PaxVax, Inc.
Executive Chairman and Chief Executive Officer
Chief Financial Officer and Executive Vice President
Chief Operating Officer and Executive Vice President
Chief Scientific Officer and Executive Vice President
Compensation as of Fiscal Year 2013.
PaxVax, Inc. Key Developments
PaxVax, Inc. Announces Executive Appointments
Mar 3 14
PaxVax Inc. announced the expansion of its commercial leadership team, including appointments of: Linda Rubinstein as Chief Financial Officer, Piers Whitehead as Chief Corporate Development Officer and Thomas Yonker as Vice President of Project Management. Ms. Rubinstein has more than 25 years of operational, financial, and capital markets experience in life science, software, and investment banking. Previously, she served as Senior Vice President and Chief Financial Officer (CFO) of Ingenuity Systems, which was acquired by QIAGEN in 2013, and Vice President and CFO of Solexa, which was acquired by Illumina in 2007. In these roles, she oversaw finance operations, conducted financing and M&A transactions, and contributed to corporate strategy. Mr. Whitehead brings 20 years of experience in the vaccines and biopharmaceutical industries to PaxVax. He joins the company from Paris-based Neovacs, where he was Vice President of Corporate Development. Prior to that, he was Vice President of Corporate and Business Development for vaccine company, VaxGen. At VaxGen, he negotiated several important partnerships and led the company's commercial strategy, resulting in the award of a nearly one billion dollar Project Bioshield Act contract. Mr. Yonker has nearly 30 years of biopharmaceutical experience, with over 25 years in project management for drug development. He joins PaxVax from Kalobios Pharmaceuticals where he managed clinical-stage projects. Prior to that, he held executive project management positions at Entelos, Abgenix, Corgentech, InterMune, Aviron, ALZA, Glaxo, and The Upjohn Company.
PaxVax, Inc. Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 09:30 AM
Feb 11 14
PaxVax, Inc. Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 09:30 AM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Kenneth J. Kelley, Executive Chairman and Chief Executive Officer.
PaxVax Announces Interim Data from Phase III Cholera Challenge Study of PXVX0200
Jan 14 14
PaxVax announced interim data from a Phase III cholera challenge study of its single-dose oral cholera vaccine candidate, PXVX0200. The investors compared the rate of diarrhoea in patients vaccinated with PXVX0200 to the rate in participants who had received a placebo. The vaccine appeared well tolerated. In an interim analysis of participants challenged at 10 days post vaccination with wild type, completely pathogenic cholera bacteria, the rate of diarrhoea was decreased in the vaccine group. 20 of 33 participants who received a placebo experienced moderate-to-severe diarrhoea compared to two of 35 participants who received PXVX0200.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 2, 2013
October 17, 2013